Editas Medicine (EDIT) Net Equity Issued and Repurchased (2015 - 2025)

Editas Medicine (EDIT) has reported Net Equity Issued and Repurchased for 9 consecutive years, with $17.1 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $17.1 million; the TTM figure through Sep 2025 stood at $25.8 million (changed N/A YoY), while the FY2023 annual figure was $117.1 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased rose to $17.1 million in Q3 2025 per EDIT's latest filing, from $7.2 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $249.5 million in Q1 2021 and bottomed at -$11000.0 in Q2 2021.
• Historically, Net Equity Issued and Repurchased has averaged $56.0 million across 3 years, with a median of $7.2 million in 2025.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 100.88% in 2021 and fell as far as 100.01% in 2021.
• Editas Medicine's Net Equity Issued and Repurchased stood at $1000.0 in 2021, then jumped by 11709900.0% to $117.1 million in 2023, then sank by 85.36% to $17.1 million in 2025.
• Business Quant data shows EDIT's Net Equity Issued and Repurchased at $17.1 million in Q3 2025, $7.2 million in Q2 2025, and $1.4 million in Q1 2025.